Plain-English translation of NCT05653453 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing a combination of tumor treating fields—a wearable device you use daily—combined with two chemotherapy drugs called gemcitabine hydrochloride and albumin-bound paclitaxel. The study wants to see if using this device alongside the medication can help people with locally advanced pancreatic cancer (cancer that has grown into nearby blood vessels but has not spread to distant parts of the body) live longer and feel better.
Pancreatic cancer that cannot be surgically removed is very difficult to treat, and current treatments have limited effectiveness. Researchers believe that adding this special device to standard chemotherapy might improve outcomes for patients who are not candidates for surgery.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will wear the tumor treating fields device every day at home. Every 28 days is considered one treatment cycle; on days 1, 8, and 15 of each cycle, you will visit the clinic to receive intravenous infusions of the two chemotherapy drugs. The study will monitor your health with blood tests and imaging scans to see how you respond to the treatment. Your participation will continue for as long as the treatment is helping and you are tolerating it well.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China